Pre-clinical work using the anti-BCMA BsAb AMG-701 (pavurutamab), an extended half-life single chain variable fragment BsAb [53], showed that pre-treatment of immune effector cells with lenalidomide or pomalidomide enhanced AMG-701-mediated MM cell killing [54]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.